SpletMulticenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy SpletAims: To investigate the predictive capacity of early post-treatment diffusion-weighted magnetic resonance imaging (MRI) for recurrence or tumor progression in patients with …
The oncological outcome and influence of neoadjuvant …
SpletBlood pressures decreased on average 12 mm Hg (95% CI 7 to 16) in the full-dose group and 6 mm Hg (95% CI 1 to 11) in the reduced-dose group, p=0.10). A hypotensive episode (mean SBP drop 53 mm Hg) was noted in 29 patients: 17 (8.3%) receiving a full dose and 12 (10.2%) receiving a reduced-dose induction, p=0.69. Splet21. apr. 2010 · To improve the compatibility of the TPF-induction without decreasing the efficacy the dose will be given on day 1 and 8 instead of applying the whole dose on day 1 every 3 weeks. In the phase I-part of the trial the optimal therapeutic dose of Docetaxel and Cisplatin will be defined. encouraged misbehavior 3 words
Dose-dense TPF induction chemotherapy for locally advanced …
Splet22. feb. 2024 · The TPF regimen consisted of docetaxel at a dose of 70–75 mg/m 2, administered as a 1-h infusion on day 1, followed by cisplatin at a dose of 70–75 mg/m 2, … Splet19. jul. 2024 · For intermediate-risk patients, reduced dose RT demonstrated promising results, with a 3-year PFS of 94.9%, which met the primary endpoint of the study. For low … Splet12. jan. 2011 · chemotherapy should be treated with TPF. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial - The Lancet Oncology Skip to Main Content Login to your account … encourage and inspire others